Clinical trials: Female Urogenital Diseases
End-stage Renal Disease, Malnutrition; Protein
Impact of IDPN on Nutrition Markers in Patients Receiving ICHD
Evaluate the impact of intradialytic parenteral nutrition (IDPN) compounded with Clinisol, Prosol, and/or Clinolipid on albumin levels and weight in patients with end-stage renal disease (ESRD) undergoing in-center hemodialysis.
- Trial name
- NCT05439174
- Testing
- Intradialytic Parenteral Nutrition
- Where
- United States
- Volunteers
- 1,200 people
- Sponsor
- Patient Care America
Acute Renal Failure
Safety Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Renal Failure
The purpose of this protocol is to evaluate the safety of a selective cytopheretic device (SCD) in patients that are on continuous renal replacement therapy (CRRT) for acute renal failure (ARF).
- Trial name
- NCT01072682
- Testing
- Selective cytopheretic device (SCD)
- Where
- 7 sites in United States
- Volunteers
- 35 people
- Sponsor
- SeaStar Medical
FSGS
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit recruitment of monocytes implicated in the inflammatory chemokine environment of…
- Trial name
- ACTION3 (NCT05183646)
- Testing
- DMX-200
- Where
- 220 sites in United States, Argentina and 19 more
- Volunteers
- 286 people
- Sponsor
- Dimerix Bioscience Pty Ltd
Glioblastoma
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
This is an event driven, adaptive design, a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 3 study of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone in patients with recurrent…
- Trial name
- NCT03149003
- Testing
- DSP-7888 Dosing Emulsion, Bevacizumab
- Where
- 61 sites in United States, Canada and 3 more
- Volunteers
- 221 people
- Sponsor
- Sumitomo Pharma America, Inc.
Renal Insufficiency, Diabetes Mellitus
Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography
It is well known that X-ray contrast media can affect kidney function in some patients, especially when administered intra-arterially, and patients who already suffer from reduced kidney function and diabetes mellitus may be at…
- Trial name
- NCT00209417
- Testing
- Iodixanol 320-Arm 1, Iopamidol 300-Arm 2
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 656 people
- Sponsor
- GE Healthcare
Advanced Malignancies
Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
The purpose of this first-in-human study of MBG453 was to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of MBG453 administered i.v.
- Trial name
- NCT02608268
- Testing
- MBG453, PDR001, Decitabine
- Where
- 14 sites in United States, Canada and 7 more
- Volunteers
- 252 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Diseases
Renasight Clinical Application, Review and Evaluation (RenaCARE) Study
This study is an open-label, multi-center study evaluating the clinical utility of Renasight in the diagnosis and management of kidney disease.
- Trial name
- RenaCARE (NCT05846113)
- Testing
- Renasight
- Where
- 31 sites in United States
- Volunteers
- 1,720 people
- Sponsor
- Natera, Inc.
Renal Disease, Chronic, Renal Disease, End-Stage
Non-invasive Testing for End-Stage Chronic Kidney Disease
This study evaluates the clinical performance of a non-invasive digital diagnostic test (KF4+, developed and manufactured by Gisens Biotech) for the measurement of urea and potassium in capillary blood in patients with end-stage…
- Conditions
- Renal Disease, Chronic, Renal Disease, End-Stage, Dialysis Patients, Urea in Blood; High
- Trial name
- NiTED (NCT07777523)
- Testing
- KF4+ Noninvasive Test
- Where
- Argentina
- Volunteers
- 55 people
- Sponsor
- Gisens Biotech
Preterm Labor
PoC Study of OBE022 in Threatened Preterm Labour
This is a proof-of-concept study in 2 parts. In Part A, patients will receive OBE022 open-label in order to assess the safety and pharmacokinetics in pregnant women with spontaneous preterm labour with a gestational age between…
- Trial name
- PROLONG (NCT03369262)
- Testing
- OBE022, Atosiban
- Where
- 18 sites in Czechia, Finland and 4 more
- Volunteers
- 115 people
- Sponsor
- ObsEva SA
Endometrial Cancer
Vaginal Fluid Collection for Detection of Endometrial Cancer
The primary objective of this study is to obtain de-identified vaginal fluid specimens from participants with an endometrial tissue biopsy-based histopathological diagnosis of endometrial cancer (EC), endometrial hyperplasia…
- Trial name
- NCT06294886
- Testing
- Screening test to detect endometrial cancer and precancer
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Innovis LLC
Urinary Retention, Catheter-Associated Urinary Tract Infection
Effectiveness and Cost-effectiveness of the T-Control® Catheter in Patients With Acute Urine Retention
The general purpose of this study is to assess the preliminary effectiveness and cost-effectiveness of the T-Control® catheter versus the Foley type catheter in patients with Acute Urine Retention.
- Conditions
- Urinary Retention, Catheter-Associated Urinary Tract Infection, Catheter Complications
- Trial name
- NCT05643950
- Testing
- Foley catheter, T-Control catheter
- Where
- 2 sites in Spain
- Sponsor
- Rethink Medical SL
Hepatocellular Carcinoma, Renal Cell Carcinoma
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
Study Design and Investigational Plan: This is an open-label Phase 1/2 study to assess the safety and tolerability of combination PD-1 inhibitor (APL-501 or nivolumab) administered concomitantly with c-Met inhibitor (APL-101), to…
- Trial name
- NCT03655613
- Testing
- APL-501, APL-101, Nivolumab
- Where
- 9 sites in Australia, New Zealand
- Volunteers
- 20 people
- Sponsor
- Apollomics (Australia) Pty. Ltd.
Fabry Disease, Chronic Kidney Disease, Stage IV (Severe)
Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme
This study was designed to determine appropriate treatment with Fabrazyme at a biweekly dose of either 1 mg/kg or 3 mg/kg in a population of patients with severe renal disease burden.
- Trial name
- NCT00837824
- Testing
- Fabrazyme (agalsidase beta)
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- Genzyme, a Sanofi Company
Menstrual Cycle Abnormal, Polycystic Ovary Syndrome
Quantum Menstrual Health Monitoring Study
The Quantum Menstrual Health Monitoring Study will measure four key reproductive hormones in the urine to characterize patterns that predict and confirm ovulation, referenced to serum hormones and the gold-standard of the…
- Conditions
- Menstrual Cycle Abnormal, Polycystic Ovary Syndrome, Athletes
- Trial name
- QMHMS (NCT05936840)
- Testing
- Mira Monitor tracking
- Where
- Canada
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Quanovate Tech Inc.
Ovarian Cancer
A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine
This is a phase 1 dose escalation trial of monotherapy misetionamide (also known as GP-2250) currently enrolling patients with platinum-resistant ovarian cancer (PROC) into Part 2 of the study.
- Trial name
- MIROC-1 (NCT03854110)
- Testing
- misetionamide (also known as GP-2250)
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Persevere Therapeutics Inc.
Renal Failure
Induction of Donor Specific Tolerance in Recipients of Live Donor Kidney Allografts by Donor Stem Cell Infusion
The goal of this research study is to establish chimerism and avoid graft-versus-host disease in patients with kidney failure allowing a reduction or cessation of immune-suppressive therapy.
- Trial name
- NCT00498160
- Testing
- Enriched Hematopoietic Stem Cell Infusion
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Talaris Therapeutics Inc.
Overactive Bladder
Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
This study will assess the efficacy of vibegron compared with placebo in men with overactive bladder (OAB) symptoms on pharmacological therapy for benign prostatic hyperplasia (BPH) as defined by micturition and urgency episodes.
- Trial name
- NCT03902080
- Testing
- Vibegron
- Where
- 140 sites in United States, Belgium and 6 more
- Volunteers
- 1,105 people
- Sponsor
- Urovant Sciences GmbH
Healthy
Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects
This study will evaluate the pharmacologic effects of exposure to darifenacin and tolterodine on cardiovascular parameters in healthy subjects 50 years of age and older
- Trial name
- NCT00703703
- Testing
- Darifenacin, Tolterodine
- Where
- 21 sites in United States
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Novartis
Lupus Nephritis
Aurinia Early Urinary Protein Reduction Predicts Response
An exploratory study assessing the ability of biomarkers measured at 8 weeks to predict clinical response over 24 and 48 weeks in subjects taking voclosporin 23.7 mg twice daily (BID) in combination with standard of care in…
- Trial name
- AURION (NCT02949973)
- Testing
- voclosporin
- Where
- 2 sites in Malaysia
- Volunteers
- 10 people
- Sponsor
- Aurinia Pharmaceuticals Inc.
Renal Insufficiency, Chronic, Kidney Disease, Chronic
A Study of LY2928057 in Hemodialysis Participants
This study will evaluate the safety of LY2928057 and how LY2928057 affects hemoglobin in hemodialysis participants. This study will involve multiple doses of LY2928057 given during a 6 week period either after a participant…
- Trial name
- NCT01991483
- Testing
- LY2928057
- Where
- 4 sites in United States
- Volunteers
- 28 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.